Brief: Moleculin Announces New Positive Independent Report Of No Cardiotoxicity In Annamycin
18/09/2023 13:49
Sept 18 (Reuters) - Moleculin Biotech Inc MBRX.O :
* MOLECULIN ANNOUNCES NEW POSITIVE INDEPENDENT REPORT OF NO
CARDIOTOXICITY IN ANNAMYCIN
* MOLECULIN BIOTECH - NEXT GENERATION ANTHRACYCLINE,
ANNAMYCIN,
DEMONSTRATED BOTH SAFETY AND PROMISING EARLY ACTIVITY ACROSS
MULTIPLE CLINICAL STUDIES
Source text for Eikon: ID:nPn8rVKHMa
Further company coverage: MBRX.O
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM